1 active not recruiting. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Active not recruiting 1 |
Follow Refractory or Relapsed Multiple Myeloma: new trials by email Literature Review of Refractory or Relapsed Multiple Myeloma trials Research Report on Refractory or Relapsed Multiple Myeloma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma CT-P44(Daratumumab), Darzalex Faspro(Daratumumab) - Refractory or Relapsed Multiple Myeloma | Phase 3 | Active not recruiting | Celltrion | 473 | 2025-08-12 | 2026-10-27 |
Multiple Myeloma (1)
Blood Protein Disorders (1) · Cardiovascular Diseases (1) · Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Hemorrhagic Disorders (1) · Hemostatic Disorders (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Lymphoproliferative Disorders (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms, Plasma Cell (1) · Paraproteinemias (1) · Vascular Diseases (1)
Celltrion (1)
Taiwan (1)